'Pay-for-delay' agreements targeted by China's planned pharma rulebook
Brand-name drugmakers are facing regulatory risks with "pay-for-delay" agreements with generic manufacturers, as China's proposed pharmaceutical guidelines classify such deals as potentially violating the country's antitrust law. In a draft released...To view the full article, register now.
Already a subscriber? Click here to view full article